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Abstract The objective of this
study was to compare the efficacy
of rizatriptan and ibuprofen in
migraine. The study was a ran-
domised placebo-controlled trial in
a tertiary care teaching hospital.
Migraine patients with <8
attacks/months were included. One
hundred and fifty-five migraine
patients were randomised to riza-
triptan 10 mg (53), ibuprofen 400
mg (52) and placebo (50). Efficacy
was assessed by headache relief,
and headache freedom at 2 h and
24 h. Two-hour headache relief
was noted in 73% in rizatriptan,
53.8% in ibuprofen and 8% in
placebo groups. Headache freedom
was achieved in 37.7% in rizatrip-
tan, 30.8% in ibuprofen and 2% in
placebo groups. Rizatriptan was
superior to ibuprofen and placebo
in relieving headache at 2 h but
not at 24 h. Side effects were
noted in 9 patients in rizatriptan, 8
in ibuprofen and 3 in placebo, all
of which were nonsignificant.
Rizatriptan and ibuprofen are supe-
rior to placebo. Rizatriptan is
superior to ibuprofen in relieving
headache, associated symptoms
and functional disability.
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Introduction
For treating acute migraine attacks, a number of drugs are
used, including ergot alkaloids, nonsteroidal anti-inflammato-
ry drugs (NSAIDS), acetaminophen and triptans. Both Cox I
and Cox II inhibitors have been investigated and found to be
effective in migraine [1, 2], however rofecoxib has been with-
drawn due to toxicity [3]. The reported efficacy of NSAIDS is
42%–72% [1, 4–7]. NSAIDS are in use because of their pre-
dictable response, low cost and well known side-effect profile.
Triptans are a new class of drugs, which are 5HT1B-D ago-
nists, quick acting and have low gastrointestinal toxicity.
Amongst the triptans, oral rizatriptan has been reported to be
more effective than sumatriptan, naratriptan and zolmitriptan
[8]. In a cross-over study, rizatriptan was found to be superior
to ergotamine and caffeine combination in relieving acute
migraine attack [9]. The decision to choose a new drug is
based not only on its efficacy compared to placebo but also its
relative advantage over other available drugs. There is no
study comparing rizatriptan with other NSAIDS. We therefore
report the results of a randomised placebo-controlled trial
(RCT) comparing rizatriptan with ibuprofen and placebo.
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Subjects and methods
This study was conducted in a tertiary care teaching hospital
during 2004–2006 and was duly approved by the local ethics
committee. The patients were recruited from out patient service
of the Neurology Department. Migraine patients above the age
of 12 years were diagnosed on the basis of International
Headache Society criteria [10]. Patients with mild (grade I)
headache, headache with recurrent vomiting or more than 8
attacks per month, pregnant or lactating mothers, and those on
oral contraceptives, or with a history of drug allergy, intractable
hypertension, renal or hepatic failure, coronary artery disease,
pulmonary, psychiatric or other neurological diseases were
excluded. The patients were subjected to detailed medical histo-
ry and physical examination as per fixed protocol. The patients
were randomised into rizatriptan, ibuprofen and placebo using
computer-generated random numbers. Randomisation was done
by one investigator and evaluation by another. The patients were
asked to record severity of headache, functional disability and
associated symptoms such as nausea, vomiting, phonophobia,
photophobia and allodynia before and 2 h after medication in a
headache diary. Relapse of headache within 24 h was also noted.
Headache relapse was defined as occurrence of moderate to
severe headache within 24 h of dosing in patients who initially
had relief of pain 2 h after medication. The severity of headache
was graded on a 0–III scale (0=normal, grade I=mild, grade
II=moderate and grade III=severe). Functional disability was
graded as 0=normal, I=daily activity mildly impaired, II=daily
activity moderately impaired, III=daily activity severely
impaired and IV=inability to perform daily activities requiring
bed rest [8]. The severity of associated symptoms of nausea,
vomiting, photophobia and phonophobia were also graded on a
0–III scale: 0=normal, I=mild, II=moderate, III=severe. The
patients were advised to take study medication (rizatriptan 10
mg, ibuprofen 400 mg or placebo) if the headache was moderate
to severe provided in identical packets. Rescue medication
piroxicam 20 mg was advised if moderate to severe headache
persisted 2 h after initial medication.
The patients were subjected to blood counts, urinalysis, blood
sugar, serum creatinine, bilirubin, serum transaminases and elec-
trocardiogram. Any side effect up to 24 h after medication was
recorded.
Efficacy measurement
Efficacy of drug was evaluated at the 1-month follow-up visit or
after 2 or more attacks, which were documented in the headache
diary. The primary end-point was percentage of patients having
pain relief at 2 h. Pain relief was considered if severity of
headache was reduced to grade I or 0. The secondary end-point
was percentage of patients with relief of associated symptoms,
functional disability at 2 h and pain freedom at 24 h.
Sample size calculation and statistics
The calculated sample size was 156, taking α=0.05, critical differ-
ence between the drugs 15% and standard deviation (SD) 2. The
power of test as evaluated for Mann-Whitney U-test was 78.62%.
The baseline characteristics between groups were compared by
independent t, χ2 and Fisher’s exact tests. The efficacy of drugs
between the groups was analysed by Mann–Whitney U-test and
within the same group by Wilcoxon signed ranked test. The num-
bers of patients with headache relief at 2 h and relapse within 24 h
were compared by χ2 test.
Results
During the study period 174 migraine patients fulfilled the
inclusion criteria. Nine patients were excluded due to lack
of consent. Fifty-seven patients were randomised to riza-
triptan, 55 to ibuprofen and 53 to placebo. Four patients in
rizatriptan and 3 each in ibuprofen and placebo were lost
from follow-up (Fig. 1). Our results therefore are based on
155 migraine patients whose age ranged between 16 and 58
(mean 30.5) years, 106 of whom were females. All the
patients had migraine without aura. The duration of
migraine ranged between 6 and 260 (mean 63.2) months.
The mean frequency of migraine attacks was 4.4 (range
2–8) per month. Eighty-seven patients had moderate and 68
severe headache. The mean headache score was 2.44±0.50,
associated symptoms score 2.08±0.29 and functional dis-
ability score 2.36±0.73. Fifty-three patients were ran-
domised to rizatriptan, 52 ibuprofen and 50 placebo groups.
The demographic and clinical variables of these groups
were not significantly different (Table 1).
Efficacy
Two-hour headache relief was achieved by rizatriptan in 39
(73%), ibuprofen in 28 (53.8%) and placebo in 4 (8%)
patients. Two-hour headache freedom was achieved by riza-
triptan in 20 (37.7%), ibuprofen in 16 (30.8%) and placebo
in 1 (2%) patients. Rizatriptan was significantly better than
ibuprofen in relieving headache (p=0.0001) but not in
achieving pain freedom (p=0.38). The headache score at 2 h
compared to baseline was significantly greater in rizatriptan
(p=0.0001) and ibuprofen (p=0.0001). Functional disability
and associated symptoms were also significantly reduced at
2 h in both rizatriptan and ibuprofen groups. However in the
placebo group, headache severity and functional disability
were significantly increased at 2 h (Table 2).
Comparing the efficacy between the groups revealed sig-
nificant improvement in headache score, associated symp-
177































Table 1 The comparison of demographic and clinical variables of migraine patients between study and control groups, which were not
significant 
Variables Rizatriptan (n=53) Ibuprofen (n=52) Control (n=50)
Age (yrs) 29.15±8.7 30.5±10.6 31.78±9.9
Females 36 38 40
Number of attacks 4.6±.13 4.2±1.2 4.5±1.4
Duration (months) 60.8±60.7 65.7±68.3 63.1±57.0
Family history 15 17 8
Nausea 53 51 43
Vomiting 47 46 46
Photophobia 53 52 50
Phonophobia 53 52 50
Functional disability 
I 3 10 4
II 28 21 22
III 21 17 23
IV 1 4 1
Severity of headache
Moderate 28 28 31
Severe 25 24 19
Duration of attack (hours) 17.0±10.3 13.6±8.8 14.8±10.9
178
toms and functional disability both in rizatriptan and
ibuprofen compared to placebo. However the difference
between rizatriptan and ibuprofen was not significant
(p=0.09). Rizatriptan resulted in significant relief in associ-
ated symptoms and functional disability and insignificant
improvement in headache score compared to ibuprofen
(Table 3). Twenty-four-hour headache relapse in the
patients who responded at 2 h was noted in 6 (15.38%) in
rizatriptan, 5 (17.85%) in ibuprofen and 1 (25%) in place-
bo groups. This difference was not significant (p=0.87). A
significantly higher number of patients needed rescue med-
ication (piroxicam 20 mg dispersible) in the placebo group
(46) compared to the rizatriptan (14) and ibuprofen (24
patients; p<0.0001) groups. Requirement of rescue medica-
tion was also significantly higher in ibuprofen compared to
rizatriptan (p=0.04).
In our study 20 patients developed side effects: 9 in riza-
triptan (palpitation 6, somnolence 2 and gastric discomfort
1), 8 in ibuprofen (gastric discomfort in all) and 3 in the
placebo group (gastric discomfort in all). The side effects
were mild to moderate and could be easily controlled with-
out any protocol violation.
Discussion
Our study reveals that rizatriptan and ibuprofen were superi-
or to placebo in relieving pain, associated symptoms and
functional disability at 2 h compared to placebo. These are in
agreement with the earlier studies in which rizatriptan 10 mg
was superior to placebo [11]. Efficacy of rizatriptan in reliev-
ing headache has been reported to be from 52% to 67.3% and
2-h pain freedom 26% to 49%. In our study rizatriptan result-
ed in headache relief in 73% and headache freedom in 37.7%
patients. Ibuprofen resulted in headache relief in 53.8% and
Table 2 Efficacy of rizatriptan, ibuprofen and placebo in patients with migraine
Drugs Before treatment 2 hour after treatment Z value p
(mean±SD) (mean±SD)
Rizatriptan (53)
Headache score 2.47±0.50 1.02±1.03 –5.85 0.0001
Functional disability score 2.38±0.63 1.04±0.98 –5.75 0.0001
Associated symptom score 2.13±0.34 0.85±0.82 –6.25 0.0001
Ibuprofen (52)
Headache score 2.44±0.54 1.35±1.14 –5.03 0.0001
Functional disability score 2.29±0.87 1.27±1.10 –5.57 0.0001
Associated symptom score 2.06±0.24 1.13±0.79 –5.48 0.0001
Placebo (50)
Headache score 2.38±0.49 2.42±0.67 –2.07 0.04
Functional disability score 2.22±0.68 2.28±0.70 –2.33 0.02
Associated symptom score 2.04±0.29 1.70±0.71 –3.00 0.0003
Table 3 Comparison of efficacy of rizatriptan, ibuprofen and placebo in acute migraine attack
Difference in score Rizatriptan Vs Ibuprofen Rizatriptan Vs placebo Ibuprofen Vs placebo
Headache 1.45±0.93 vs 1.12±1.08 1.45±0.93 vs 0.16±0.51 1.12±1.08 vs 0.16±0.51
Z/p value –1.69/0.09 –6.68/0.0001 –5.10/0.0001
Associated symptoms 1.25±0.83 vs 0.90±0.85 1.25±0.83 vs 0.26±0.66 0.90±0.85 vs 0.26±0.66
Z/p value –2.06/0.04 –5.82/0.0001 –4.33/0.0001
Functional disability 1.34±0.90 vs 0.98±0.94 1.34±0.90 vs 0.14±0.40 0.98±0.94 vs 0.14±0.40
Z/p value –21.3/0.03 –6.78/0.0001 –5.38/0.0001
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headache freedom in 30.8% patients. The efficacy of ibupro-
fen in earlier studies has been reported to be 42%–70% [4, 7,
12, 13].
On comparing with ibuprofen, rizatriptan was better in
relieving pain, associated symptoms and functional disabili-
ty at 2 h. Rizatriptan has been compared with other triptans
and is reported to be superior to sumatriptan, zolmitriptan
and naratriptan in 2-h pain relief and 24-h headache freedom
[8]. Acetaminophen, aspirin and NSAIDS in migraine have
been found to be effective and well tolerated in adults and
children [4, 14]. In childhood migraine, ibuprofen has been
found to be superior to acetaminophen [4]. There is howev-
er no study comparing the relative efficacy of rizatriptan and
NSAIDS. Triptans, especially sumatriptan, have been com-
pared with naproxen, indomethacin, aspirin and ibuprofen
[14–16]. In an RCT, ibuprofen resulted in headache relief in
62.5%, sumatriptan in 55.8% and headache freedom was
33.2% and 37.1% patients respectively, which were not sig-
nificant [14]. In our study, rizatriptan resulted in significant
pain relief, reduction in associated symptoms and functional
disability compared to ibuprofen. Gastrointestinal side
effects were more common with ibuprofen and palpitations
with rizatriptan; however, the side effects were not severe
enough to warrant discontinuation in any patient.
Our study is limited by the relatively small number of
patients. As the study was conducted in a single centre, there
is homogeneity in patient selection and low inter-rater vari-
ability. Efforts were made to blind the randomising and eval-
uating investigators and medication was provided in identi-
cal packets to eliminate bias.
Both rizatriptan and ibuprofen are superior to placebo in
aborting acute migraine attack. Rizatriptan 10 mg is superi-
or to ibuprofen in relieving headache, associated symptoms
and functional disability.
